Kathrine Morin

Katie Morin focuses her practice on corporate law.

Katie's corporate law practice is focused on assisting private equity firms and their portfolio clients and emerging and high-growth companies in connection with a variety of transactional needs, including mergers and acquisitions, leveraged buyouts, debt and equity offerings, minority investments, corporate reorganizations and general corporate counseling. She also has experience serving as general outside counsel to public and private companies.

Katie also has public finance experience encompassing a wide variety of matters relating to the issuance of tax-exempt and taxable bonds, including representation of issuers and borrowers in connection with general obligation and revenue bond transactions. She has served as bond counsel to various cities, towns and quasi-public agencies.

Katie has been involved in the following transactions: 

• Led the representation of Imugene Ltd. in the strategic transaction with Precision Biosciences in which Imugene received a worldwide exclusive license to Precision Bioscience’s allogenic CD19 CAR T-cell therapy program for oncology and a related manufacturing facility for total deal consideration valued up to $227 million
• Led the representation of Ambac Financial Group Inc., a financial services holding company, in the purchase of a majority stake in Riverton Insurance Agency, Corp., a New Jersey-based insurance services business
• Led the representation of Legacy Farms LLC, a leading fresh vegetable and fruit grower, shipper and wholesaler to grocers and foodservice providers in the Western United States, in the acquisition of Frieda’s, a California-based specialty produce distributor
• Led the representation of Ambac Financial Group Inc., a financial services holding company, in the purchase of a majority stake in both All Trans Risk Solutions and Capacity Marine Corporation
• Represented Biohaven Pharmaceutical Company Ltd. (NYSE: BHVN) in the sale of its migraine business to Pfizer in a total deal consideration valued at approximately $13 billion
• Assisted in the representation of Greenbacker Capital Management in its investment in Sunrock Distributed Generation
• Led the representation of Oscor, Inc., in its sale of $220 million to Integer Holdings Corporation
• Represented American Tower Corporation in the acquisition of data centers located in Orlando and Atlanta operated by DataSite
• Represented Silver Oak Services Partners, LLC, in the recapitalization of Drive Automotive Services, LLC
• Led the representation of Enhanced Energy Group, Inc., operating as CarbonPoint Solutions, in its sale to Caterpillar Inc.
• Assisted in the representation of Shanghai Haohai Biological Technology Co., Ltd., in connection with its $40 million Series A preferred equity investment in Eirion Therapeutics, Inc., and related licensing agreements
• Assisted in the representation of Silver Oak Services Partners, LLC, in its sale of BBG, Inc., to Incline Equity Partners
• Assisted in the representation of KPS Mid-Cap Investments, an affiliate of KPS Capital Partners, in the acquisition of Libertas Copper LLC
• Assisted in the representation of Biohaven Pharmaceutical Holding Company in its acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc., that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab
• Assisted in the representation of the Seller of Falk Marques Group to Pageant Media US Limited
• Led the representation of Biohaven Pharmaceutical Holding Company and its affiliate BioShin Limited in a $60 million Series A preferred equity financing of BioShin Limited, BioShin’s subsidiary